Abstract
Influenza pandemics arise when novel influenza virus subtypes emerge in populations with little or no pre-existing immunity. The recent expansion of H5N1 virus circulation in mammals - including documented spread in cattle and sporadic human infections - coupled with the emergence of mutations associated with enhanced pandemic potential, underscores the persistent threat of novel influenza strains. Pandemic preparedness critically depends on developing effective vaccines capable of providing broad protection across diverse viral strains. While vaccination remains the most effective strategy for preventing influenza and its complications, pandemic vaccine development faces substantial challenges. These include the rapid mutation rates characteristic of influenza viruses, driven by error-prone RNA replication, broad host range, environmental selection pressures, and frequent genetic recombination. Such factors complicate predictions of which strain will trigger the next pandemic and hinder efforts to create universal vaccines. Recent advances in vaccine production platforms, bioinformatics, and artificial intelligence have accelerated pandemic vaccine development capabilities. Continued research is essential to enhance vaccine technology, expedite production timelines, and broaden vaccine efficacy against the full spectrum of influenza virus strains.